Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

被引：3
|
作者：
Allen, Pamela [1 ]
Chen, Qing C. [2 ]
Lu, Xinyan [2 ]
O'Shea, Kaitlyn [3 ]
Chmiel, Joan [4 ]
Sukhanova, Madina [2 ]
Slonim, Liron Barnea [2 ]
Savas, Hatice [5 ]
Mou, Eric [6 ]
Pro, Barbara [7 ]
Evens, Andrew M. [8 ]
Palmer, Brett Alan [7 ]
Advani, Ranjana [9 ]
Gordon, Leo I. [7 ]
Winter, Jane N. [7 ]
机构：
[1] Emory Univ, Winship Canc Inst, Decatur, GA USA
[2] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Northwestern Univ, Dept Biostat, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA
[6] Stanford Univ, Dept Med, Div Oncol, Palo Alto, CA USA
[7] Northwestern Univ, Div Hematol & Oncol, Chicago, IL 60611 USA
[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[9] Stanford Canc Inst, Saul A Rosenberg Prof Lymphoma, Dept Med, Div Oncol, Stanford, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147042
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
231
引用
收藏
页数：4
相关论文
共 44 条
  • [31] High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis
    Greb, Alexander
    Bohlius, Julia
    Trelle, Sven
    Schiefer, Daniel
    De Souza, Carmino A.
    Gisselbrecht, Christian
    Lntragumtornchai, Tanin
    Kaiser, Ulrich
    Kluin-Nelemans, Hanneke C.
    Martelli, Maurizio
    Milpied, Noel Jean
    Santini, Gino
    Verdonck, Leo F.
    Vitolo, Umberto
    Schwarzer, Guido
    Engert, Andreas
    CANCER TREATMENT REVIEWS, 2007, 33 (04) : 338 - 346
  • [32] Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma
    Glass, Bertram
    Altmann, Bettina
    Stelljes, Matthias
    Lenz, Georg
    Marx, Julia
    Hasenkamp, Justin
    Kroschinsky, Frank P.
    Saidy, Anna Ossami
    Dreger, Peter
    Mueller, Lutz Peter Hermann
    Hilgendorf, Inken
    Illerhaus, Gerald
    Kobbe, Guido
    Schroers, Roland
    Linke, Katrin
    Koehler, Carsta
    Schmitz, Norbert
    Ziepert, Marita
    van Heteren, Pearl
    BLOOD, 2023, 142
  • [33] High-dose chemotherapy with autologous stem cell support is not superior to conventional-dose chemotherapy in the first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis.
    Greb, A
    Schiefer, DH
    Bohlius, J
    Schwarzer, G
    Engert, A
    BLOOD, 2004, 104 (11) : 263A - 263A
  • [34] Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience
    Viviani, Simonetta
    Di Nicola, Massimo
    Bonfante, Valeria
    Di Stasi, Antonio
    Carlo-Stella, Carmelo
    Matteucci, Paola
    Magni, Michele
    Devizzi, Liliana
    Valagussa, Pinuccia
    Gianni, Alessandro M.
    LEUKEMIA & LYMPHOMA, 2010, 51 (07) : 1251 - 1259
  • [35] Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results
    Pettengell, Ruth
    Zinzani, Pier Luigi
    Narayanan, Geetha
    de Mendoza, Fernando Hurtado
    Digumarti, Raghunadharao
    Gomez, Henry
    Coiffier, Bertrand
    Schiller, Gary
    Rizzieri, David A.
    Cernohous, Paul
    Wang, Lixia
    Singer, Jack
    BLOOD, 2010, 116 (21) : 1168 - 1169
  • [36] Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: Results of a GLSG-Subgroup analysis in patients with relapsed indolent lymphoma.
    Dreyling, Martin H.
    Forstpointner, Roswitha
    Boeck, Hans-Peter
    Repp, Roland
    Wandt, Hannes
    Pott, Christiane
    Seymour, John Francis
    Metzner, Bernd
    Haenel, Annette
    Lehmann, Tanja
    Hartmann, Frank
    Einsele, Hermann
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2006, 108 (11) : 784A - 784A
  • [37] First-line treatment with single agent rituximab, followed by maintenance rituximab plus anti-idiotype Id-KLH active immunotherapy vaccine (FavId) in patients (pts) with low-grade non-Hodgkin lymphoma (NHL): Preliminary results of a phase II trial
    Raefsky, E.
    Greco, F. A.
    Spigel, D. R.
    Litchy, S.
    Gian, V.
    Bender, J.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] High-dose chemotherapy with autologous stem cell support does not improve outcome in the first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis
    Greb, A
    Bohlius, J
    Schwarzer, G
    Schiefer, D
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 55 - 55
  • [39] Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study
    Barraclough, Allison
    Chong, Geoff
    Gilbertson, Michael
    Grigg, Andrew
    Churilov, Leonid
    Fancourt, Tineke
    Ritchie, David
    Koldej, Rachel
    Agarwal, Rishu
    Manos, Kate
    Smith, Charmaine
    Houdyk, Kristen
    Hawking, Joanne
    Hawkes, Eliza
    BLOOD, 2019, 134
  • [40] Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
    O'Connor, Owen A.
    Moskowitz, Craig
    Portlock, Carol
    Hamlin, Paul
    Straus, David
    Dumitrescu, Otilia
    Sarasohn, Debra
    Gonen, Mithat
    Butos, John
    Neylon, Ellen
    Hamelers, Rachel
    Mac-Gregor Cortelli, Barbara
    Blumel, Susan
    Zelenetz, Andrew D.
    Gordon, Leo
    Wright, John J.
    Vose, Julie
    Cooper, Brenda
    Winter, Jane
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (01) : 34 - 39
12345